Successful use of cyclosporine A in the treatment of refractory thrombotic thrombocytopenic purpura.
Thrombotic thrombocytopenic purpura (TTP) is, in most cases, treatable with plasma exchange therapy (PLEX). Rarely, patients do not respond to PLEX or develop refractory disease despite an initial remission. In these cases, treatment options are limited and the response to established alternative therapies is often disappointing. We report the case of a paediatric patient with TTP who developed refractory disease after an initial response to PLEX. She was subsequently treated with cyclosporine A and showed an immediate and sustained response. CSA may be a safe and effective therapy for patients with refractory TTP and should be studied in randomized, prospective clinical trials.
Hand
J P
JP
Department of Pediatrics, University of British Columbia, British Columbia's Children's Hospital, Vancouver, Canada.
Lawlor
E R
ER
Yong
C K
CK
Davis
J H
JH
D000293:Adolescent; D002908:Chronic Disease; D016572:Cyclosporine / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D010951:Plasma Exchange; D010976:Platelet Count; D011697:Purpura, Thrombotic Thrombocytopenic / Q000188:drug therapy*; D012008:Recurrence
D016572:Cyclosporine